Precision BioSciences, Inc. (DTIL)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$6.22−$0.1100 (−1.74%) on the dayAs of the close; data may be delayed.
DTIL price, last 12 months
Key stats
- Previous close
- $6.33
- Open
- $6.35
- Day range
- $6.18 – $6.55
- 52-week range
- $3.53 – $9.62
- Volume
- 204K
- Avg volume (20 days)
- 257.4K
- Market cap
- $171.7M
Performance
1W−6.8%
1M−26.7%
3M−14.7%
6M−4.9%
YTD+49.5%
1Y+21.3%
vs S&P 500, 1Y+4.5 pts
Technicals and fundamentals
About Precision BioSciences, Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $171.7M